Disposition of Vorinostat, A Novel Histone Deacetylase Inhibitor and Anticancer Agent, in Preclinical Species
Paul A. Andrews,
Maribeth P. Baker,
Kenneth A. Koeplinger,
Eric D. Soli,
Thomas A. Baillie.
The disposition of vorinostat, an anticancer agent, was investigated in rats and dogs. Vorinostat possessed high serum clearance, a short elimination half-life and low oral bioavailability in both species. The renal route played an important role in the elimination of drug-related material and vorinostat was eliminated primarily by metabolic biotransformation.
Keywords: Vorinostat, histone deacetylases, glucuronidation, β-oxidation, 4-anilino-4-oxobutanoic acid
Rights & PermissionsPrintExport